Denali Therapeutics (NASDAQ:DNLI) announced its quarterly earnings data on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.13), Fidelity Earnings reports. The company had revenue of $1.20 million for the quarter, compared to analyst estimates of $3.00 million.
Denali Therapeutics stock traded down $0.67 during mid-day trading on Friday, reaching $16.68. The company had a trading volume of 207,840 shares, compared to its average volume of 368,850. Denali Therapeutics has a fifty-two week low of $12.32 and a fifty-two week high of $25.79. The firm has a market capitalization of $1.65 billion and a P/E ratio of -2.83.
In other Denali Therapeutics news, insider Carole Ho sold 17,500 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $21.72, for a total value of $380,100.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ryan J. Watts sold 18,334 shares of the firm’s stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $18.05, for a total transaction of $330,928.70. The disclosure for this sale can be found here. Insiders sold 54,167 shares of company stock worth $1,060,456 in the last 90 days. Company insiders own 21.30% of the company’s stock.
Separately, Zacks Investment Research cut shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $23.25.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/11/10/denali-therapeutics-dnli-issues-earnings-results-misses-estimates-by-0-13-eps/2973348.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.